Company Filing History:
4 out of 2,405 
4 out of 52 
Years Active: 2021-2025
Title: Kornelia Schultze: Innovator in Antibody Development
Introduction
Kornelia Schultze is a prominent inventor based in Jena, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of four patents to her name, her work focuses on innovative solutions for treating cancer.
Latest Patents
Among her latest patents is the invention of Anti-ILT4 antibodies and antigen-binding fragments. This invention provides antibodies and fragments that specifically bind to ILT4 (immunoglobulin-like transcript 4). The patent also includes combinations with an anti-PD1 antibody, offering potential methods for treating or preventing cancer in subjects. Additionally, it outlines methods for producing these antibodies and fragments, showcasing her commitment to advancing cancer treatment.
Career Highlights
Kornelia has worked with notable companies in the biotechnology sector, including Merck Sharp & Dohme Corporation and Agenus Inc. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Throughout her career, Kornelia has collaborated with talented individuals such as Barbara Joyce-Shaikh and Luis A Zuniga. These partnerships have enriched her work and fostered innovation in antibody development.
Conclusion
Kornelia Schultze's contributions to the field of biotechnology, particularly in the development of anti-ILT4 antibodies, highlight her role as a leading inventor. Her work not only advances scientific knowledge but also holds promise for improving cancer treatment options.